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Abstract 25 
The mechanical consequences of skeletal microdamage have been clearly documented 26 
using various experimental methods yet recent experiments suggest that physiological 27 
levels of microdamage accumulation are not sufficient to compromise the bones’ 28 
biomechanical properties.  While great advances have been made in our understanding 29 
of the biomechanical implications of microdamage, less is known concerning the 30 
physiological role of microdamage in bone remodeling.  Microdamage has been shown 31 
to act as a signal for bone remodeling, likely through a disruption of the osteocyte-32 
canalicular network.  Interestingly, age-related increases in microdamage are not 33 
accompanied by increases in bone remodeling suggesting that the physiological 34 
mechanisms which link microdamage and remodeling are compromised with aging.   35 
 36 
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Introduction 40 
Microdamage accumulation in bone is a normal physiological event which is the 41 
consequence of repeated cycles of loading during activities of daily living (1, 2).  Under 42 
normal physiological conditions, the microscopic cracks that are formed in bone are 43 
arrested by the morphological features and heterogeneous material properties of bone, 44 
and then are repaired by bone remodeling.  These processes are usually in balance, 45 
although under circumstances of aging (3) or suppression of remodeling by 46 
pharmaceutical agents (4-6) the balance between microdamage formation and 47 
replacement can enter disequilibrium, and damage can accumulate to levels that are 48 
significantly higher than in healthy, untreated bone.  49 
 50 
What are the biomechanical consequences of microdamage accumulation? 51 
Bone biomechanical properties exist at two hiearchial levels, those of the whole bone 52 
(routinely called structural properties) and those of the tissue itself (routinely called 53 
material properties) (7, 8).  Structural properties, including ultimate load, stiffness, and 54 
work to failure, are dependent on variables such as bone mass, geometry/architecture, 55 
and the material properties of the tissue.  Material properties, including ultimate stress, 56 
modulus, and modulus of toughness, are determined by various components of the 57 
mineral (e.g., degree and heterogeneity of mineralization) and organic matrix (e.g., 58 
collagen content and extent of cross-linking).    59 
 60 
In laboratory studies, it has been shown that the initiation and growth of microscopic 61 
cracks reduces the overall strength (9) and stiffness of bone (10).  This has often been 62 
interpreted as suggesting that microdamage in bone makes it more prone to fracture.  63 
Indeed, damage in both biological and non-biological materials is defined by engineers 64 
as the loss of stiffness (11, 12), and a common criterion for failure that has been used in 65 
the past is damage equals or exceeds a 30% loss of the original stiffness of the material 66 
(13).  Yet microdamage is also known to serve as an outlet for energy dissipation by 67 
relieving stress (14). If microcracks were prevented from forming, it is likely that bone 68 
would fail with less deformation, and in a more brittle fashion.  This may be one reason 69 
for the longer fatigue life of bone from younger donors than from older donors as 70 
younger donors tend to form lots of small microcracks in localized areas rather easily 71 
(diffuse damage), whereas older donors relieve stresses by forming fewer but longer 72 
linear microcracks (15).  The energy dissipation properties of microcrack formation are 73 
exemplified by the observation that very tough materials – those that require a lot of 74 
energy to break – typically form cracks easily, but prevent their growth through 75 
incorporation of materials of varying stiffness within their structure.  These contrasting 76 
effects of microdamage on biomechanical properties, -- reduction of residual strength 77 
and stiffness but enhanced toughness -- derived mainly through ex vivo laboratory 78 
experiments, make it difficult to predict the biomechanical implications of microdamage 79 
in the living skeleton.   80 
   81 
Studies using animal models have explored the relationships between microdamage and 82 
biomechanical properties in depth.  These experiments have shown that an increased 83 
microdamage burden is associated with reduced tissue toughness, but not with 84 
alterations in any other biomechanical parameters (4, 5, 16, 17).  This modulus of 85 
toughness is a reflection of the energy required to cause failure at the material level, and 86 
is defined as the total area under the stress-strain curve derived from a mechanical test 87 
(8).  Cause and effect between microcrack accumulation and reduced toughness has 88 
never been demonstrated at the levels to which microdamage can accumulate in the 89 
body during normal physiological circumstances, even with suppression of remodeling 90 
using pharmaceutical agents. Therefore, it is not clear that microdamage accumulation 91 
in bone under normal physiological circumstances is even a relevant biomechanical 92 
concern for living bone. 93 
 94 
Suppressing bone remodeling in intact, non-estrogen deficient dogs for one year using 95 
doses of bisphosphonates approved by the FDA for treatment of Paget’s disease or 96 
osteoporosis, and used under other circumstances to prevent bone loss and skeletal 97 
metastasis in certain kinds of cancer, allowed a 2- to 4-fold increase in microdamage 98 
accumulation in the lumbar vertebrae (5), and a 4- to 7-fold increase in the ribs (17). 99 
These early studies used high doses of oral bisphosphonate which were criticized for 100 
being 5x higher than those used to treat postmenopausal osteoporosis (PMO). Although 101 
the doses were comparable to those used clinically for the treatment of Paget’s disease 102 
and therefore relevant to human disease, patients with Paget’s disease would never take 103 
these high doses of bisphosphonates for more than a few months, certainly never for as 104 
long as a year, which was the treatment period in these experiments.  More recent 105 
experiments using lower doses comparable to those used for the treatment of PMO 106 
demonstrate conclusively that suppression of remodeling, even at these clinically-107 
relevant lower doses, is associated with a 3- to 4-fold increase in microdamage 108 
accumulation in the lumbar vertebrae of non-osteoporotic dogs (4) (FIG 1). Milder 109 
suppression of turnover, either using doses of bisphosphonates below the clinical dose 110 
equivalent or an FDA approved selective estrogen receptor modulator (SERM – 111 
raloxifene) still allowed a significant increase in microdamage accumulation (4, 18).  112 
These latter changes occurred with as little as a 20% reduction in turnover rate showing 113 
that virtually any reduction in the site-specific rate of remodeling allows microdamage to 114 
accumulate.  115 
 116 
Whether the level of microdamage accumulation in these experiments alters the 117 
mechanical properties of the bone is open to question.  While several experiments have 118 
shown that animals treated with bisphosphonates have increased microdamage and 119 
reduced toughness (4, 5, 16-18), the direct relationship between these changes has yet 120 
to be defined.  Recent data from the dog model has provided several pieces of evidence 121 
suggesting there is not a direct relationship between levels of microdamage produced in 122 
vivo and changes in bone toughness.  The most convincing evidence of this lack of 123 
cause/effect comes from aging dogs.  Treatment of  dogs which were a year old at the 124 
initiation of treatment for either one or three years with saline vehicle (analogous to an 125 
aging model) showed an age-related decline in vertebral bone remodeling, an age-126 
related increase in microdamage, yet no age-related difference in vertebral bone 127 
toughness (19) (FIG 2).  If microdamage were a key contributor to reduced bone 128 
toughness, significant differences in toughness should have been noted between these 129 
animals of different ages.  These data are supported by the general lack of congruence 130 
between changes in microdamage and toughness among various bisphosphonate-131 
treatment groups (FIG 1).  For example, a 3- to 3.5-fold increase in damage 132 
accumulation at doses of bisphosphonates used for osteoporosis is associated with 133 
toughness reductions of between 5 and 17%, whereas a ~5-fold increase in damage at 134 
the higher doses is associated with toughness reductions in the same range (10-14%) 135 
(4, 5).  Moreover, these experiments yield a weak, non-significant r2 value of 0.01 for 136 
correlations between microdamage accumulation and toughness (FIG 3).  Collectively, 137 
these data strongly indicate that factors other than microdamage accumulation are 138 
principally responsible for the reductions in toughness reported with bisphosphonate 139 
treatment and physiological levels of in vivo microdamage have minimal effect on 140 
biomechanics.   141 
 142 
What is the role of microdamage in bone remodeling?  143 
Frost originally proposed a link between microcracks and remodeling based on the 144 
concept that repairing microdamage would be essential to prevent catastrophic failure of 145 
the bone (2).  This has been demonstrated several times by different laboratories using 146 
different animal models and is now considered an integral component of bone 147 
remodeling physiology (20-24) (FIG 4).   148 
 149 
The concept of microdamage initiating bone remodeling was first addressed 150 
experimentally using a dog limb overloading model (25).  This study found that localized 151 
regions of bone with higher amounts of microdamage also had higher numbers of 152 
resorption cavities yet the association between the two was not explored in detail.  153 
Subsequent experiments in which physiological external loads were imparted to induce 154 
microdamage in canine forelimbs showed that four days post-loading there was an 155 
association between microdamage and resorption spaces that was >40 times higher 156 
than would be predicted by chance (26).  Although later re-analyses of the data 157 
suggested the association to be lower (6x higher association than by chance) but still 158 
significant, these data provided strong evidence of a physiological relationship between 159 
microdamage and remodeling (27).  It remained possible, however, that the 160 
microdamage generated by loading preferentially developed in regions undergoing 161 
remodeling (28).  This alternative hypothesis was tested by comparing levels of 162 
microdamage and remodeling eight days after in vivo loading to levels immediately 163 
following loading in canine forelimbs (29).  The levels of microdamage in both loading 164 
groups were significantly higher than in non-loaded limbs while there were higher levels 165 
of resorption cavities only in those limbs that had been loaded eight days earlier.  A 166 
significant number of the resorption cavities were associated with microdamage (FIG 5), 167 
providing convincing evidence that microdamage served as an initiator for remodeling.  168 
More recent studies using similar experimental methods in a sheep model have 169 
documented temporal loading-induced changes in microdamage and remodeling, 170 
showing that both parameters peak and return to control levels at similar times post-171 
loading (30). 172 
 173 
While the studies in canine bone provided the foundation for defining the physiological 174 
role of microdamage in initiating remodeling, the most convincing studies to show the 175 
relationship between microdamage formation and remodeling utilized external fatigue 176 
loading in a rat model (31).  Rats do not normally undergo intracortical resorption, so the 177 
finding of both microdamage and intracortical resorption spaces in the cortex following 178 
loading has unequivocally shown the cause/effect relationship between these 179 
parameters.  Ten days after fatigue loading both microdamage and intracortical 180 
resorption spaces were noted in the ulna with preferential location of the remodeling 181 
cavities near sites of damage (31).  Further proof of a relationship from this experiment 182 
comes from the fact that two rats which did not have microdamage following loading also 183 
did not have intracortical resorption cavities.  Findings of damage and remodeling in the 184 
rat model have been shown in subsequent studies by this same group (32) as well as by 185 
others (33-35).  Recent evidence of loading-induced microdamage and remodeling in 186 
mice (36) will likely open the door for future work using transgenic animals to understand 187 
the molecular signals connecting microdamage and remodeling.  188 
 189 
Additional insight into the relationship between microdamage and remodeling has been 190 
gained from the studies using beagle dogs treated with anti-remodeling agents.  Dogs 191 
treated with anti-remodeling agents (either bisphosphonates or raloxifene) or allowed to 192 
naturally age, accumulate significant amounts of microdamage in the ribs and vertebrae; 193 
the magnitude of accumulation  is inversely correlated to the level of turnover 194 
suppression (4, 5, 16-19, 37).  These studies have provided important information 195 
concerning the relationship between microdamage and remodeling.  Suppression of 196 
remodeling leads to reductions in both targeted and non-targeted remodeling (38).   197 
Large reductions in remodeling suppression are not essential for accumulation of 198 
damage, with turnover suppression of only 20% sufficient for a significant 2-fold increase 199 
in vertebral damage accumulation (18).  Finally, the increases in microdamage with 200 
remodeling suppression is most rapid during the early phase of treatment such that 201 
prolonged  remodeling suppression does not significantly increase levels of damage 202 
beyond those accumulated early in treatment (19).  This plateau in damage 203 
accumulation is likely explained by other changes associated with prolonged remodeling 204 
suppression that limit damage formation such as increased bone mass which reduces 205 
localized strains below the damage threshold (39).  This would lead to a new equilibrium 206 
between damage initiation and remodeling being achieved over time.  Such a new 207 
equilibrium would be consistent with physiological levels of microdamage not 208 
compromising biomechanical integrity.  209 
  210 
The idea of targeted remodeling, originally theorized by Frost (2), was put forth as a 211 
viable mechanism through which the bone could minimize accumulation of damage and 212 
prevent fatigue failure (40).  Based on the early data from canine loading experiments, 213 
approximately 30% of all remodeling in cortical bone has been suggested to be targeted 214 
toward removal of microdamage (29, 41).  Whether the remaining 70% is truly random, 215 
or whether it is targeted to other areas of bone, for example regions that have high 216 
strain, are highly mineralized, or have compromised osteocyte integrity, is unclear (24, 217 
41).  Martin has suggested that in a normal, healthy skeleton all cortical bone remodeling 218 
is targeted to microdamage (42).  Using a mathematical model, he was able to 219 
computationally explain how the experimental evidence for targeted remodeling 220 
underestimates the association between microcracks and remodeling cavities because 221 
of the 2D assessment of these 3D structures (microcracks).  One criticism of the idea 222 
that all remodeling serves the purpose of removing microdamage is that remodeling 223 
units are typically several millimeters in length (43), thus the need to remove such a 224 
large amount of tissue for the sake of removing a single microcrack is difficult to 225 
understand.  To address this concern, Martin developed a follow-up model showing how 226 
this could be reconciled through an osteonal steering mechanism, where remodeling 227 
units that are formed and targeted to remove a specific microcrack can then steer their 228 
trajectory in order to remodel other nearby cracks (44).     229 
 230 
The mechanism(s) through which microdamage signals bone remodeling is not 231 
understood although most evidence points to a disruption in the osteocyte/canalicular 232 
network.   Data from the rat fatigue loading model have shown significantly higher 233 
numbers of apoptotic osteocytes near microdamage within the loaded limb compared to 234 
the non-loaded limb of the same animal, or sites within the loaded limb that are distant 235 
from microdamage (32, 33, 45).  Osteocyte apoptosis is elevated as soon as twenty-four 236 
hours post-loading, thus preceding the appearance of remodeling cavities, and appears 237 
to be coordinated through key regulators of the apoptosis pathway including Bax and 238 
Bcl-2 (32, 45).  Osteocytes near cracks have increased expression of Bax, a pro-239 
apoptotic signal, while those more distant from microdamage have increased expression 240 
of Bcl-2, an anti-apoptotic signal, effectively creating a target for remodeling (45).  These 241 
data provide intriguing evidence that dying osteocytes signal remodeling to regions of 242 
bone containing microdamage.  But why do the osteocytes die with fatigue loading?  The 243 
most prominent hypothesis is that osteocyte processes are physically broken by 244 
microdamage, disrupting cell-to-cell communication and fluid flow (20, 23).  This is 245 
supported by the abundance of evidence showing fluid flow plays a key role in osteocyte 246 
physiology (21, 46, 47) and that both fluid flow (35, 48) and cell process connections 247 
(49) are disrupted following fatigue loading.  The nature of the cellular and molecular 248 
mechanisms underlying damage-related targeted remodeling should be a key focus of 249 
future microdamage research.   250 
 251 
Aging bone: An exception to the rules of microdamage and remodeling 252 
Age-related changes to bone tissue properties, such as decreased mineralization 253 
heterogeneity and increased collagen cross-linking, make the bone more susceptible to 254 
microdamage (50).  It would be expected that increases in microdamage formation with 255 
age would be held in check by remodeling, yet there exists a clear age-associated 256 
increase in microdamage accumulation (3, 51-55), indicative of a breakdown in the 257 
microdamage-remodeling feedback loop.  Bone remodeling tends to increase with age 258 
(56) and can be enhanced further with anabolic agents such as parathyroid hormone 259 
(57), illustrating that aged bone retains the ability to remodel.  This suggests that 260 
dysfunction with age is in the signal(s) coming from the damaged regions.  One possible 261 
explanation is that the signal originating from the tissue surrounding microdamage is 262 
compromised with age such that the remodeling units do not recognize the tissue has 263 
been damaged.   Osteocyte number declines with age (58), and with fewer cells, the 264 
strength of the remodeling signal may be diminished.  Fewer cells and canaliculi would 265 
also reduce the probability of a given crack breaking a sufficient number of osteocyte cell 266 
processes to initiate the signal.  Another potential explanation could be that the signal for 267 
remodeling exists but for some reason is not adequately transmitted to the osteoclasts 268 
(or it is delivered but not properly interpreted).  Reductions in osteocyte numbers with 269 
age, as well as reduced mechanical loads from physical activity, would be expected to 270 
reduce fluid flow through the bone which could in turn compromise the dissemination of 271 
soluble signals coming from osteocytes.  Finally, age-associated changes in osteocyte 272 
gene expression could result in down-regulation of the signal for targeted remodeling.  273 
No matter what the dysfunction ultimately turns out to be, the key concept is that by 274 
studying this disconnect between microdamage and remodeling with aging we are likely 275 
to gain a better understanding of their normal physiological interaction.  276 
 277 
Conclusions 278 
Recent data from in vivo experiments provide convincing evidence that physiological 279 
levels of microdamage accumulation do not compromise the biomechanical properties of 280 
bone.  This suggests that in the absence of pathological levels of skeletal damage, the 281 
biomechanical implications of microdamage are likely insignificant with respect to 282 
fracture risk.  The more important role of microdamage in bone physiology appears to be 283 
for initiating and targeting of bone remodeling.  The intimate link between microdamage 284 
and remodeling is clear yet the specifics concerning the mechanisms underlying the 285 
signals remain an area for future study.   286 
 287 
Figure Legends 288 
Fig 1.  Minimal congruence exists between changes in microdamage and toughness.  289 
Following one year of treatment, microdamage in the vertebra of beagle dogs is 290 
significantly increased in animals treated with bisphosphonates (risedronate (RIS) or 291 
alendronate (ALN)) or raloxifene (RAL) compared to vehicle-treated animals.  The level 292 
of toughness reductions compared to vehicle controls, none of which were statistically 293 
significant, showed little relation to the level of microdamage increase. Data adapted 294 
from (4, 18). 295 
 296 
Fig 2.  Physiological increases in microdamage through aging-related reductions in bone 297 
remodeling are not associated with compromised bone toughness.  Untreated dogs, 298 
assessed at two- and four-years of age, showed significant (* p < 0.05) age-related 299 
reductions in trabecular bone remodeling (activation frequency) and age-related 300 
increases in microdamage accumulation (microcrack density) of the vertebra.  Despite 301 
over a 3-fold increase in microdamage with age, modulus of toughness, the energy 302 
absorption capacity of the bone tissue, was similar between the two groups suggesting 303 
that physiological increases in microdamage do not play a prominent role in altering 304 
bone toughness.  Data adapted from (19).   305 
 306 
 307 
Fig 3.  Lack of correlation between microdamage and toughness.  The level of 308 
microdamage accumulation (crack surface density) within trabecular bone of the 309 
vertebra from animals treated for 1 or 3 years with various anti-remodeling agents 310 
(alendronate, risedronate, or raloxifene) or vehicle controls showed no relationship to 311 
toughness (r2 = 0.01).  Data adapted from (4, 18, 19). 312 
 313 
Fig 4.  Bone remodeling, initiated by a microcrack and the associated osteocyte 314 
apoptosis.  Reprinted from (22) with permission from publisher.  Copyright © [2006] 315 
Massachusetts Medical Society.  All rights reserved. 316 
 317 
Fig 5.  Microdamage as a target for bone remodeling.  Photomicrograph depicts a basic 318 
remodeling unit (*) within cortical bone traveling toward a microcrack (arrowhead). 319 
 320 
 321 
 322 
 323 
 324 
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